oxcarbazepine

(redirected from Oxtellar XR)
Also found in: Medical.
Related to Oxtellar XR: Trokendi XR
Translations

oxcarbazepine

n oxcarbazepina
References in periodicals archive ?
M2 EQUITYBITES-June 23, 2016-Supernus awarded seventh US patent protecting its antiepileptic drug Oxtellar XR
M2 PHARMA-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
M2 EQUITYBITES-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
M2 PHARMA-September 3, 2015-Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
It has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
Additionally, Supernus Pharmaceuticals has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
M2 EQUITYBITES-September 3, 2015-Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
M2 PHARMA-September 5, 2014-Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
M2 PHARMA-January 8, 2014-Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
M2 EQUITYBITES-September 5, 2014-Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
Specialist pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) said on Monday that the US Food and Drug Administration (FDA) has granted the company's Oxtellar XR with three years of market exclusivity.
M2 EQUITYBITES-January 8, 2014-Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy